Characterization of the T- and B-cell immune response to a new recombinant pre-S1, pre-S2 and SHBs antigen containing hepatitis B vaccine (Hepagene™); evidence for superior anti-SHBs antibody induction in responder mice

Hepagene™ is a novel recombinant particle consisting of the pre‐S1, pre‐S2 and small surface (SHBs) antigens (Ag) of the hepatitis B virus (HBV) and is adjuvanted with alhydrogel in the final formulation. It has been primarily developed to enhance anti‐SHBs antibody titres in inadequate responders,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of viral hepatitis 1998-11, Vol.5 (s2), p.5-8
Main Authors: Jones, C. D., Page, M., Bacon, A., Cahill, E., Bentley, M., Chatfield, S. N.
Format: Article
Language:English
Subjects:
Animals
antibody responses
B-Lymphocytes - immunology
Enzyme-Linked Immunosorbent Assay
Hepagene™ vaccine
Hepatitis B - prevention & control
Hepatitis B Antibodies - biosynthesis
Hepatitis B Antibodies - immunology
Hepatitis B Surface Antigens - immunology
Hepatitis B Vaccines - immunology
Hepatitis B virus
Immunoglobulin G - immunology
Lymphocyte Activation
Mice
Mice, Inbred BALB C
Protein Precursors - immunology
Recombinant Proteins - immunology
T-cell responses
T-Lymphocytes - immunology
Vaccination
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepagene™ is a novel recombinant particle consisting of the pre‐S1, pre‐S2 and small surface (SHBs) antigens (Ag) of the hepatitis B virus (HBV) and is adjuvanted with alhydrogel in the final formulation. It has been primarily developed to enhance anti‐SHBs antibody titres in inadequate responders, to conventional SHBsAg vaccines. Since non‐compliance is also a problem with existing HBV vaccine schedules, the ability to accelerate current immunization regimens to provide more rapid protection has also been an important objective. Here we describe the T‐ and B‐cell responses to Hepagene™ in two strains of responder mouse (BALB/c and SWR/J).
ISSN:1352-0504
1365-2893
DOI:10.1046/j.1365-2893.1998.0050s2005.x